Skip to main content
. 2021 Aug 4;161(2):448–457. doi: 10.1016/j.chest.2021.07.2162

Figure 3.

Figure 3

A, B, Lines graphs showing 6MWD initially and at end of study for riociguat (A) (P < .025) and placebo (B) (P > .05). End-of-study visit for riociguat was more than 330 days for all but one patient who dropped out at 98 days. End-of-study visit for patients who received placebo ranged from 145 to 365 days, with five patients at less than 330 days. 6MWD = 6-min walk distance.